Yoshimitsu Soga1, Mitsuyoshi Takahara2, Osamu Iida3, Kenji Suzuki4, Shinsuke Mori5, Daizo Kawasaki6, Kazuki Haraguchi7, Terutoshi Yamaoka8, Kenji Ando1. 1. Department of Cardiology, Kokura Memorial Hospital. 2. Department of Metabolic Medicine, Osaka University Graduate School of Medicine. 3. Cardiovascular Center, Kansai Rosai Hospital. 4. Department of Cardiology, Tokyo Saiseikai Central Hospital. 5. Department of Cardiology, Yokohama-city Tobu Hospital. 6. Department of Cardiology, Morinomiya Hospital. 7. Department of Cardiology, Shin-Koga Hospital. 8. Department of Vascular Surgery, Matsuyama Red Cross Hospital.
Abstract
AIM: More than 5-year clinical outcomes after femoropopliteal (FP) stenting with bare-nitinol stent (BNS) have not yet been unclear. We investigate the long-term patency and mortality following FP stenting with BNS. METHODS: This study was a multicenter retrospective study of a prospectively maintained database. From April 2004 to December 2011, 1824 consecutive patients (2211 limbs) who underwent FP stenting with BNS for de novo lesions were selected and analyzed. Primary endpoint was primary patency which was defined as treated vessel without restenosis and reintervention and its associated factors. RESULTS: The prevalence of diabetes mellitus and dialysis was 60.5% and 23.8%, respectively. Chronic limb-threatening ischemia (CLTI) accounted for 30.8%. Chronic total occlusion (CTO) was found in 52.7%, and lesion length was more than 20 cm in 22.6%. During the median follow-up of 3.8 years (interquartile range, 1.4 to 7.4 years), 1049 cases lost patency, whereas 355 cases were dead without experiencing loss of patency. The primary patency (95% CI) was estimated to be 74.8%, 47.3% and 29.1% at 1-, 5- and 10-year. On multivariate analysis, female sex, age ≥ 80 years, diabetes, dialysis, CLTI, CTO, arterial calcification, long lesion (＞20 cm), and small vessel (≤ 4 mm) were the independent predictors of primary patency after FP stenting. In addition, the prognostic impact of age ≥ 80 years, CLTI, and arterial calcification was significantly attenuated afterwards (P＜0.05). CONCLUSIONS: Ten-year patency after BNS implantation for FP disease has been continuously reducing up to 10 years and the prognostic impact of risk factors was changed over time.
AIM: More than 5-year clinical outcomes after femoropopliteal (FP) stenting with bare-nitinol stent (BNS) have not yet been unclear. We investigate the long-term patency and mortality following FP stenting with BNS. METHODS: This study was a multicenter retrospective study of a prospectively maintained database. From April 2004 to December 2011, 1824 consecutive patients (2211 limbs) who underwent FP stenting with BNS for de novo lesions were selected and analyzed. Primary endpoint was primary patency which was defined as treated vessel without restenosis and reintervention and its associated factors. RESULTS: The prevalence of diabetes mellitus and dialysis was 60.5% and 23.8%, respectively. Chronic limb-threatening ischemia (CLTI) accounted for 30.8%. Chronic total occlusion (CTO) was found in 52.7%, and lesion length was more than 20 cm in 22.6%. During the median follow-up of 3.8 years (interquartile range, 1.4 to 7.4 years), 1049 cases lost patency, whereas 355 cases were dead without experiencing loss of patency. The primary patency (95% CI) was estimated to be 74.8%, 47.3% and 29.1% at 1-, 5- and 10-year. On multivariate analysis, female sex, age ≥ 80 years, diabetes, dialysis, CLTI, CTO, arterial calcification, long lesion (＞20 cm), and small vessel (≤ 4 mm) were the independent predictors of primary patency after FP stenting. In addition, the prognostic impact of age ≥ 80 years, CLTI, and arterial calcification was significantly attenuated afterwards (P＜0.05). CONCLUSIONS: Ten-year patency after BNS implantation for FP disease has been continuously reducing up to 10 years and the prognostic impact of risk factors was changed over time.
Authors: E Minar; B Pokrajac; T Maca; R Ahmadi; C Fellner; M Mittlböck; W Seitz; R Wolfram; R Pötter Journal: Circulation Date: 2000-11-28 Impact factor: 29.690
Authors: Michael S Conte; Andrew W Bradbury; Philippe Kolh; John V White; Florian Dick; Robert Fitridge; Joseph L Mills; Jean-Baptiste Ricco; Kalkunte R Suresh; M Hassan Murad Journal: J Vasc Surg Date: 2019-05-28 Impact factor: 4.268
Authors: William A Gray; Koen Keirse; Yoshimitsu Soga; Andrew Benko; Anvar Babaev; Yoshiaki Yokoi; Henrik Schroeder; Jeffery T Prem; Andrew Holden; Jeffrey Popma; Michael R Jaff; Juan Diaz-Cartelle; Stefan Müller-Hülsbeck Journal: Lancet Date: 2018-09-24 Impact factor: 79.321
Authors: Victor Aboyans; Jean-Baptiste Ricco; Marie-Louise E L Bartelink; Martin Björck; Marianne Brodmann; Tina Cohnert; Jean-Philippe Collet; Martin Czerny; Marco De Carlo; Sebastian Debus; Christine Espinola-Klein; Thomas Kahan; Serge Kownator; Lucia Mazzolai; A Ross Naylor; Marco Roffi; Joachim Röther; Muriel Sprynger; Michal Tendera; Gunnar Tepe; Maarit Venermo; Charalambos Vlachopoulos; Ileana Desormais Journal: Eur Heart J Date: 2018-03-01 Impact factor: 29.983
Authors: Peter A Schneider; John R Laird; Gheorghe Doros; Qi Gao; Gary Ansel; Marianne Brodmann; Antonio Micari; Mehdi H Shishehbor; Gunnar Tepe; Thomas Zeller Journal: J Am Coll Cardiol Date: 2019-01-25 Impact factor: 24.094
Authors: Martin Schillinger; Schila Sabeti; Christian Loewe; Petra Dick; Jasmin Amighi; Wolfgang Mlekusch; Oliver Schlager; Manfred Cejna; Johannes Lammer; Erich Minar Journal: N Engl J Med Date: 2006-05-04 Impact factor: 91.245
Authors: Giovanni Torsello; Konstantinos Stavroulakis; Marianne Brodmann; Antonio Micari; Gunnar Tepe; Pierfrancesco Veroux; Andrew Benko; Donghoon Choi; Frank E G Vermassen; Michael R Jaff; Jia Guo; Reka Dobranszki; Thomas Zeller Journal: J Endovasc Ther Date: 2020-06-25 Impact factor: 3.487